secwatch.observer — SEC 8-K summary
======================================

Issuer:     Emmaus Life Sciences, Inc. (EMMA)
CIK:        0000822370
Form:       8-K
Filed at:   2022-05-13T23:59:59+00:00
Accession:  0001213900-22-026112
Event type: earnings
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Emmaus Q1 revenue drops 40% to $3.2M; cash falls to $0.8M; working capital insufficient
--------------------------------------------------------------------------------

- Net revenue $3.2M, down from $5.3M YoY; sell-through improved but overstocking by distributors hit revenue.
- Net loss to common stockholders $1.5M ($0.03/share), improved from $8.4M loss ($0.17/share) in Q1 2021.
- Loss from operations widened to $3.1M from $1.6M; operating expenses reduced to $5.3M from $6.5M.
- Cash $0.8M at March 31, 2022; management says working capital insufficient for 2022 without additional financing.
- Launched Endari telehealth program; Florida Medicaid added Endari to preferred drug list; received UAE marketing authorization.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/822370/000121390022026112/0001213900-22-026112-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/822370/000121390022026112/ea159763-8k_emmaus.htm
  HTML page:      https://secwatch.observer/filing/0001213900-22-026112

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer